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LAY ABSTRACT
Using a tool named cost-utility analysis, this study in-
vestigated whether rehabilitation combined with a given 
drug (abobotulinumtoxinA) for post-stroke spasticity is 
cost-effective (i.e. affordable) vs rehabilitation alone 
for both the Italian National Health Service and society. 
Over a period of 2 years, this study shows that each ad-
ditional year weighted for health-related quality of life 
(quality-adjusted life year; QALY) gained via rehabilita-
tion combined with abobotulinumtoxinA vs rehabilita-
tion alone for post-stroke spasticity costs the Italian Na-
tional Health Service and society €12,341 and €23,601, 
respectively (2018 values). Given the Italian informal 
acceptability range (i.e. the maximum amount decision-
makers are supposed to pay) for additional QALY gained 
(€25,000–40,000), these results support the conclusion 
that rehabilitation combined with abobotulinumtoxinA is 
a cost-effective (i.e. good value for money) healthcare 
programme for treating patients with post-stroke spas-
ticity in Italy.
Objective: To investigate costs and quality-adjusted 
life years of rehabilitation combined with abobotuli-
numtoxinA (aboBoNT-A) (rehab/aboBoNT-A) vs re-
habilitation alone (rehab) in post-stroke spasticity 
in Italy.
Design: Based on both Italian National Health Ser-
vice and societal perspectives, a 2-year cost-utility 
analysis model was performed.
Subject/patients: The cost-utility analysis model 
considered hypothetical patients.
Methods: The cost-utility analysis model was popu-
lated with data concerning demographics, disease 
severity, healthcare and non-healthcare resource 
consumption. Data were collected via a questionn-
aire administered to 3 highly experienced Italian 
physiatrists (864 out of 930 post-stroke spasticity 
patients on rehab/aboBoNT-A in total). Costs are ex-
pressed in Euro (€) based on the year 2018.
Results: The cost to society (rounded to the nea-
rest whole €) was €22,959 (rehab/aboBoNT-A) vs 
€11,866 (rehab). Italian National Health Service-
funded cost was €7,593 (rehab/aboBoNT-A) vs 
€1,793 (rehab). Over a period of 2 years rehab/
aboBoNT-A outperforms rehab in terms of quality-
adjusted life years gained (1.620 vs 1.150). The 
incremental cost-utility ratio was €12,341 (Italian 
National Health Service viewpoint) and €23,601 (so-
cietal viewpoint). Sensitivity analyses confirmed the 
robustness of the baseline results. 
Conclusion: Despite some limitations, the higher 
number of quality-adjusted life years gained vs re-
hab and the high probability of reaching a cost-utili-
ty ratio lower than the Italian informal acceptability 
range (€25,000–40,000) make rehab/aboBoNT-A 
a cost-effective healthcare programme for treating 
patients with post-stroke spasticity in Italy.
Key words: stroke; spasticity; abobotulinumtoxinA; rehabili-
tation; cost-utility analysis; Italy.
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Post-stroke spasticity (PSS) is described as velocity-dependent increased muscle tone with exaggerated 
tendon jerks subsequent to stroke, resulting from hype-
rexcitability of the stretch reflex. Its prevalence ranges 
from 4% to 27% in the early post-stroke phase (1–4 
weeks post-stroke), 19% to 26.7% in the post-acute 
phase (1–3 months post-stroke), and 17% to 42.6% in 
the chronic phase (>3 months post-stroke) (1). 
Spasticity can vary from a mild neurological sign 
to a significant increase in muscle tone that might 
affect joint mobility. Notably, PSS can be associated 
with a negative impact on activities of daily living 
(ADL) (1).
Botulinum toxin type A (BoNT-A) is an effective 
treatment for focal spasticity in stroke survivors, and is 
approved by the US Food and Drug Administration and 
European regulatory agencies for this indication. BoNT-
A is an enzyme that acts in the cytosol of nerve endings 
*A provisional version of this research has been given as an oral presentation 
at the TOXINS 2019 conference, Copenhagen, Denmark, 17 January 2019 
(speaker: Alessio Baricich, MD, PhD).
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to cleave synaptosomal-associated protein (SNAP)-25, 
resulting in blocked acetylcholine release at neuromus-
cular junctions (2). Intramuscular injections of BoNT-A 
are currently considered the gold standard for treatment 
of PSS, due to its effectiveness in reducing spastic 
hypertonia with low prevalence of complications. In 
addition, BoNT-A might reduce disability in patients 
affected by PSS, improving patients’ participation in 
ADLs and health-related quality of life (HRQoL) (3). 
AbobotulinumtoxinA injection (aboBoNT-A; Dy-
sport®, Ipsen Pharma SAS, Paris) has been shown to be 
a safe and effective treatment for PSS (4), which impro-
ves rehabilitation outcomes (5, 6) and relieves pain (7).
In order to investigate the costs and QALYs of reha-
bilitation + BoNT-A (rehab/aboBoNT-A) vs rehabilita-
tion (rehab) in Italy, a 2-year, model-based cost-utility 
analysis (CUA) was performed (8, 9).
METHODS
Decision tree
All authors participated in a meeting aimed at exploring the 
feasibility of this research project. Hence, it was not pos-
sible to apply the approach used in other studies on the cost-
effectiveness of BoNT-A (10, 11), the Delphi panel (12), since 
the methodological requirement of anonymity of the panellists 
was breached (12). Thus, as suggested in the literature for this 
situation (12), the qualified opinion of a sample of convenience 
(13) of 3 highly experienced Italian physiatrists (comprising 930 
post-stroke patients with upper or lower limb spasticity treated 
in total; 864 on rehab/aboBoNT-A and 66 on rehab only) who 
co-authored this research (AB: 170 on rehab/aboBoNT-A and 30 
on rehab only; AP: 456 on rehab/aboBoNT-A and 24 on rehab 
only; AS: 238 on rehab/aboBoNT-A and 12 on rehab only) was 
elicited to estimate, via an ad hoc questionnaire, most of the 
parameters that were used for populating the CUA model (see 
Supplementary Tables SM1–SM241). 
To obtain the mean value for each parameter, these estimates 
were weighted for the proportion of 930 post-stroke patients 
with upper or lower limb spasticity on rehab/aboBoNT-A 
or rehab that were followed by each physiatrist. Physiatrists 
stratified patients using the Ashworth scale according to their 
PSS severity (14). 
Costs, life-years saved (LYS) and QALYs of hypothetical 
patients on rehab/aboBoNT-A and rehab were calculated via 
a decision tree (15) developed using Microsoft Excel® 2010 
(Microsoft, Redmond, WA, USA). 
Consistent with the time horizon covered by a previous study 
of HRQoL in patients with PSS (16), the decision tree covers a 
2-year period, during which patients can move from post-stroke 
survival (i.e. the starting health state when patients enter the 
model) to stroke-related death or death due to other causes (17, 
18). Transitions between these 3 health states are probabilistic 
(15, 19) (Fig. 1). 
1http://www.medicaljournals.se/jrm/content/?doi=10.2340/16501977-2636
Fig. 1. Model outline. Rehab: rehabilitation; Rehab/aboBoNT-A: abobotulinumtoxinA + rehabilitation.
Post-stroke spasticity
Rehabilitation + BoNT-A 
Rehabilitation
Survival (1st year)
p(Survival (1st year))=0.937
Post-stroke death (1st year)
Death due to other reasons (1st year)
p(Death due to other reasons(1st year))=0.009
Survival (2nd year)
p(Survival (2nd year) | Survival (1st year))=0.957 
p(Post-stroke death (2nd year) | Survival (1st year))=0.033
Death due to other reasons (2nd year)
p(Death due to other reasons(1st year) | Survival (1st
year))=0.010
nd
Post-stroke death (2nd year)
p(Post-stroke death (1st year))=0.054
Survival (1st year)
p(Survival (1st year))=0.937
Survival (2 year)
p(Survival (2nd year) | Survival (1st year))=0.957 
p(Post-stroke death (2nd year) | Survival (1st year))=0.033
Post-stroke death (2nd year)
Death due to other reasons (2nd year)
p(Death due to other reasons(1st year) | Survival (1st
year))=0.010Post-stroke death (1st year)
p(Post-stroke death (1st year))=0.054
Death due to other reasons (1st year)
p(Death due to other reasons(1st year))=0.009
=decision node
=chance node
=end of the pathway
www.medicaljournals.se/jrm
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Utility and QALYs
QALYs synthesize improvements in both length of life and de-
sirability of health state with time (8, 9). Calculation of QALYs 
implies multiplying LYS accrued to patients by a synonym for 
HRQoL experienced by patients, named utility (8, 9). Utility 
ranges between 0 (death or other health state perceived worse 
than death) and 1 (perfect health) (8, 9). 
For the 2 years considered in the CUA model, PSS utility for 
rehabilitation patients was obtained from the literature (first 
year: 0.60; second year: 0.64) (16) (Table SM231): hence, the 
first and second years lived with PSS by patients in rehabilitation 
correspond to 0.60 and 0.64 years lived in full health.
For rehab/aboBoNT-A patients, a percentage improvement 
(range 0–100%) in utility vs rehab patients was elicited from 
physiatrists and used to express rehab/aboBoNT-A patients’ 
utility as a multiple of rehab patients’ utility (Table SM241). 
Physiatrists’ perception was based on improved mobility and 
ADL experienced by their patients on rehab/aboBoNT-A vs 
those on rehab.
As a half-cycle correction was applied (15), 6-month costs, 
LYS and QALYs were calculated for patients who had died 
from stroke sequelae or other causes (Tables SM81 and SM101), 
as these patients were assumed to die halfway through each 
1-year period.
Resource identification, quantification and valuation
As the economic evaluation adopted both the Italian National 
Health Service (INHS) and the societal perspective (8), con-
sumption of healthcare and non-healthcare resources was valued. 
Healthcare resources funded by INHS included: aboBoNT-A 
and intramuscular administration (in outpatient or day-hospital 
setting); rehabilitation sessions (in outpatient, day-hospital or 
home setting); ultrasounds and physiatrist follow-up visits; 
mobility aids (crutches; orthosis; shoulder braces; walking aids; 
wheelchairs); baclofen (per os or intrathecal); pregabalin per os; 
physiatrist and neurologist visits, drugs, electromyography and 
rehabilitation sessions due to rare aboBoNT-A-related adverse 
events (AEs), such as botulinic syndrome and chronic urticaria 
(Tables SM1–SM91; and SM11–SM151). 
Healthcare services provided in outpatient, day-hospital or 
inward hospital settings were costed according to outpatient or 
hospital tariffs, assumed as a reasonable proxy of the real costs 
borne by healthcare facilities (20) (Tables SM19–SM211). As it 
was administered in the hospital setting only, aboBoNT-A was 
costed at its ex-factory price (which is approximately 33% less 
than the consumer price (CP)). The other drugs were costed 
at their CP (Table SM21). Assuming a 5-year useful life for 
those healthcare goods that support patients beyond the year 
of purchase (e.g. walking aids), a 5-year straight-line deprecia-
tion approach (8) was adopted for calculating their yearly cost 
(Tables SM20 and SM211). 
The mean cost for each AE was determined by multiplying 
the cost of its management by its incidence (1/5,000 patients, as 
reported by 1 of the physiatrists in his clinical practice) (Tables 
SM21 and SM81). Costs to patients and their families consist of 
out-of-pocket expenses, patient loss of working days and informal 
care (8). Out-of-pocket expenses include healthcare resources 
that are not funded by the INHS (shockwave sessions; additional 
private home rehabilitation sessions; antihistamine/corticosteroid 
for skin rash management; some type of orthosis and walking 
canes), as well as all non-healthcare resources (car transport to 
and from home/healthcare facility; parking at healthcare facility; 
home help , that is a person whose job is to help ill people at their 
homes with activities such as cooking and cleaning.) (Tables SM11 
and SM2; S6; SM14–SM16; Tables SM221). 
Consistent with the gross wage rate approach (21), the daily 
cost of a home help includes net wage, social security contribu-
tion and taxation, as specified by the national labour agreement) 
(Tables SM161 and SM221). The gross wage rate approach was 
also applied to value the working days lost by the patient while 
undergoing healthcare services and by caregivers in providing 
informal care (Tables SM171 and SM18; SM221). If the patient 
was unemployed, not engaged in housekeeping or retired (≥ 70 
years old), working time was replaced by leisure time, which 
was costed according to the take-home wage rate (net wage 
only) (21) (Table SM221). Carers were assumed to be employed 
or housewives. The daily cost of a patient’s carer was considered 
a good proxy for costing housewife’s time (20) (Table SM221).
Costs were expressed in Euro (€) based on the year 2018 per 
patient and updated to that year according to inflation rates for 
healthcare services or for general consumption whenever neces-
sary (22). A 3% annual real social discount rate was applied to 
costs, LYS, and QALYs (8, 9, 23) (Table SM21).
As the CUA model is not a clinical trial, no ethics committee 
approval of the study protocol (including the above-mentioned 
questionnaire) was required by current Italian legislation (24).
Cost-utility analysis
The difference in costs and QALYs of alternative healthcare 
programmes (incremental approach) compared via CUA is 
calculated and summarized via the incremental cost-utility 
ratio (ICUR), which is the ratio of incremental costs (ΔC) to 
incremental QALYs (ΔQALYs) (8, 9).
In general, the ICUR provides decision-makers with the 
cost of obtaining an incremental QALY with the healthcare 
programme that has a better effect on patient’s HRQoL, but is 
also more costly than the comparator(s).
Statistical analysis
Point estimate and 95% confidence interval (95% CI) were 
calculated for most of the parameters included in the CUA 
model and for ICURs (15, 19, 25). Whenever an analytical 
calculation was not possible, the standard error for parameters 
was calculated by imposing an appropriate coefficient of varia-
tion on their point estimate (15, 19, 25, 26). For parameters that 
were not given a statistical distribution, a range was reported. 
No hypothesis test was performed.
Sensitivity analyses
The uncertainty of the base case ICUR was explored by one-way 
and probabilistic sensitivity analyses (8, 9). Parameters included 
in one-way sensitivity analysis were varied individually, holding 
the others at their baseline values (8, 9).
One-way sensitivity analysis examined the variations in 
ICUR due to changes in all the parameters classified as event 
probabilities; resource consumption; unit cost; utility for PSS 
patients on rehab; utility multiplier for PSS patients on rehab/
aboBoNT-A; post-stroke standardized mortality ratio (SMR). In 
addition, the 3% baseline real social discount rate was changed 
(0%; 5%) to test its influence on ICUR over the 2-year period 
covered by the CUA model (8, 9). 
Apart from real social discount rate, parameters included in 
one-way sensitivity analysis were varied by replacing their ba-
seline point estimate with the lower and upper limits of the 95% 
CI resulting from appropriate statistical distributions, which 
J Rehabil Med 52, 2020
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≥ 3 categories, such as attending to INHS-funded rehabilitation 
sessions in outpatient, day-hospital or home setting). Post-stroke 
SMR was given a log-normal distribution, whereas unit costs as 
well as utility multiplier for patients on rehab/aboBoNT-A were 
assumed to be normally distributed A gamma distribution was 
used to represent uncertainty in resource consumption. The re-
sults of one-way sensitivity analysis are displayed as departures 
from the baseline ICUR on a Tornado chart. The relationship 
between ICUR and time was investigated by reducing the CUA 
model time-span from 2 years to 1 year. 
Probabilistic sensitivity analysis assessed the joint parameter 
uncertainty affecting the base case ICUR via a 10,000-itera-
tion Monte Carlo simulation (8, 9, 15, 19) and supported the 
calculation of the 95% CI of ICURs (percentile method) (26, 
27). For each Monte Carlo iteration, a random value was drawn 
from the statistical distribution fitted to each parameter inclu-
ded in probabilistic sensitivity analysis (15, 19). An algebraic 
manipulation of the ICER (net monetary benefit) supported the 
construction of the cost-effectiveness acceptability curve, which 
was applied to Monte Carlo simulation results to graphically 
represent the uncertainty concerning the cost-effectiveness of 
rehab/aboBoNT-A and rehab (15, 19, 28). Drug posology and 
costs were not included in sensitivity analyses (19).
RESULTS
Decision tree
Notional patients enter the CUA model aged 66 (range 
40–79) years; the probability of being female is 0.475 
(Table I). The expected survival probability after the first 
year is the same for both rehab/aboBoNT-A and rehab 
patients (0.937), as is the conditional probability of being 
alive in the second year having survived the first year 
(0.957) (Fig. 1). The probability of death unrelated to 
stroke increases by 0.01 from the first to the second year.
Most patients (0.928) are prescribed rehab/aboBoNT-
A (Table I). Patients on rehab/aboBoNT-A are more 
likely to be severe than those on rehab (mild PSS: 0.148 
vs 0.624; moderate PSS: 0.332 vs 0.355; severe PSS: 
0.287 vs 0.011; very severe PSS: 0.233 vs 0.011) (Table 
I). AboBoNT-A is more likely to be administered in 
day-hospital (0.925) than in outpatient setting (0.075) 
and its posology, which is consistent with PSS severity, 
ranges from 500 potency unit (U) for mild impairment 
to 1,500–2,000 U for very severe impairment (Table I). 
Patients with severe or very severe PSS on rehab/
aboBoNT-A or on rehab have different probability of 
being active workers (0.052 vs 0.00). The probability 
of being employed with no reduction in working hours 
due to PSS is 0.700 for both rehab/aboBoNT-A and 
rehab (Table I). The average number of working days 
lost due to PSS treatment is 33.97 (range 6.76–70.27) 
for patients on rehab/aboBoNT-A and 9.74 (range 
1.56–39.89) for those on rehab (Table I).
Among female patients, the probability of being a 
housewife ranges from 0.417 for rehab/aboBoNT-A to 
0.439 for rehab (Table I). 
were fitted to each type of parameter or their range (15, 19, 26). 
Beta distribution was fitted to binomial data (e.g. a parameter 
that encompasses 2 categories, such as being employed or not) 
and utility values for rehab patients. A Dirichlet distribution was 
given to multinomial data (e.g. a parameter that encompasses 
Table I. Main quantitative non-monetary results from the cost-
utility analysis (CUA) model
Item/parameter
Point 
estimate 
LL 95% CI 
or range
UL 95% 
CI range
Patient’s age, years 66 40a 79a
Probability female patient 0.475 0.443b 0.507b
Probability rehab/aboBoNT-A 0.928 0.443b 0.507b
Severity of PSS 
Rehab/aboBoNT-A
Mild 0.148 0.125 0.173
Moderate 0.332 0.299 0.367
Severe 0.287 0.247 0.327
Very severe 0.233 0.190 0.278
Rehab
Mild 0.624 0.505 0.735
Moderate 0.355 0.184 0.548
Severe 0.011 0.000 0.085
Very severe 0.011 0.000 0.086
Probability DH administration Rehab/
aboBoNT-A 0.925 0.906b 0.941b
Mean U per injection Rehab/aboBoNT-A
Mild 500.00 500.00a 500.00a
Moderate 909.14 650a 1,000a
Severe 1,500 1,500a 1,500a
Very severe 1,634.41 1,500a 2,000a
Probability of being employed 
Rehab/aboBoNT-A
Mild 0.388 0.306 0.474
Moderate 0.233 0.186 0.284
Severe 0.052 0.028 0.082
Very severe 0.052 0.026 0.086
Rehab
Mild 0.415 0.272 0.566
Moderate 0.260 0.108 0.450
Severe 0.000 0.000 0.000
Very severe 0.000 0.000 0.000
Probability of being employed without 
working hours reduction 0.700 0.670b 0.729b
Probability of being a housewife 
Rehab/aboBoNT-A 0.417 0.370b 0.465b
Rehab 0.439 0.273b 0.611b
Productivity losses, days
Rehab/aboBoNT-A 33.97 6.76 70.27
Rehab 9.74 1.56 39.89
Probability of home help needed 
Rehab/aboBoNT-A 0.411 0.379b 0.444b
Rehab 0.384 0.272b 0.503b
Probability of informal care needed
Rehab/aboBoNT-A
Mild 0.327 0.296c 0.359c
Moderate 0.538 0.502c 0.574c
Severe 0.796 0.743c 0.843c
Very severe 0.796 0.737c 0.848c
Rehab
Mild 0.246 0.151c 0.356c
Moderate 0.349 0.180c 0.542c
Severe 0.608 0.367c 0.822c
Very severe 0.608 0.366c 0.823c
Informal care (days)
Rehab/aboBoNT-A 10.63 1.77 11.50
Rehab 1.72 0.31 2.60
aRange. bBeta distribution 95% CI (15, 19). cConditional Beta distribution 95% 
CI (15, 19).95% CI: 95% confidence interval; DH: day-hospital; LL: lower 
limit; PSS: post-stroke spasticity; Rehab: rehabilitation; Rehab/aboBoNT-A: 
abobotulinumtoxinA + rehabilitation; U: potency unit; UL: upper limit.
www.medicaljournals.se/jrm
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The probability of needing home help depends on 
being on rehab/aboBoNT-A (0.411) or rehab (0.384) 
(Table I).
The probability of needing informal care varies 
according to the severity of PSS and also differs bet-
ween rehab/aboBoNT-A and rehab (mild PSS: 0.327 
vs 0.246; moderate PSS: 0.538 vs 0.349; severe PSS: 
0.796 vs 0.608; very severe PSS: 0.796 vs 0.608) 
(Table I).
On average, patients on rehab/aboBoNT-A re-
ceive 10.63 days of informal care (range 1.77–11.50), 
whereas for patients on rehab caregivers are engaged 
1.72 days (range 0.31–2.60) (Table I).
Cost, QALYs and cost-utility analysis
The cost borne by society for rehab/aboBoNT-A and 
rehab is €22,959 and €11,866, respectively (Table II).
INHS-funded cost for rehab/aboBoNT-A and rehab 
are €7,593 and €1,793 (33.07% vs 15.11% of the overall 
cost); out-of-pocket expenses are €11,402 and €8,820 
(49.66% vs 74.33% of the overall cost), whereas pro-
ductivity losses and informal care amount to €3,964 and 
€1,254 (17.26% vs 10.56% of the overall cost).
For both healthcare programmes the cost-driver is 
home help (35.85% and 64.83% of the overall cost for 
rehab/aboBoNT-A and rehab, respectively).
It is noteworthy that the largest share of overall cost 
(rehab/aboBoNT-A: 49.66%; rehab: 74.33%) is funded 
out-of-pocket by the patient and their families. These 
amounts also include healthcare resources that are not 
funded by INHS (e.g. additional home rehabilitation 
sessions).
Despite no difference in mortality (LYS 1.858 per 
patient for both rehab/aboBoNT-A and rehab), during 
the 2-year period rehab/aboBoNT-A outperforms rehab 
in terms of QALYs gained (1.620 vs 1.150 per patient), 
since the mean value of the utility multiplier for patients 
on rehab/aboBoNT-A as elicited from the 3 physiatrists 
who co-authored this research is 1.409 (i.e. for each year 
covered by the CUA model the utility for PSS patients 
on rehab/aboBoNT-A was considered +40.86% than the 
utility experienced by PSS patients on rehab).
Following the INHS and societal viewpoints, due to 
incremental cost of €5,801 and €11,093 coupled with 
incremental QALYs (0.470 for both perspectives), 
the ICUR, that is the cost for obtaining an incremen-
tal QALY with rehab/aboBoNT-A vs rehab, reaches 
€12,341 (95% CI: €6,206; €42,242) and €23,601 (95% 
CI: €8,408; €84,485) (Table III).
Sensitivity analyses
The Tornado chart shows that, from the perspective 
of both INHS and society, the largest variations in the 
baseline ICURs are caused by changes in the utility 
multiplier for post-stroke patients on rehab/aboBoNT-
A (from –40.32% to +208.33% vs base case ICUR) 
(Fig. 2A and B). 
Replacing the base case number of INHS-funded 
rehabilitation sessions prescribed to rehab/aboBoNT-
A patients with moderate PSS per year causes the 
base case ICURs estimate to vary between –12.67% 
Table II. Base case analysis: costs per patient (2018)
Cost items
Rehab/
aboBoNT-A, € % Rehab, € %
Italian National Health Service cost 
AboBoNT-A 2,160.42 9.41 0.00 0.00
Administration 735.36 3.20 0.00 0.00
Rehabilitation 3,747.06 16.32 1,392.58 11.74
Follow-up 570.34 2.48 50.38 0.42
AboBoNT-A-related AEs 0.21 0.001 0.00 0.00
Other healthcare resources 208.54 0.91 182.72 1.54
Mobility aids 171.29 0.75 166.96 1.41
Total (A) 7,593.23 33.07 1,792.65 15.11
Patients and their families cost – out-of-pocket expenses
Rehabilitation 147.68 0.64 51.71 0.44
Mobility aids 16.00 0.07 15.89 0.13
AboBoNT-A-related AEs 0.14 0.001 0.00 0.00
Other healthcare resources 227.83 0.99 227.83 1.92
Transportation 2,389.43 10.41 688.73 5.80
Parking 390.80 1.70 143.58 1.21
Home help 8,230.30 35.85 7,692.37 64.83
Total (B) 11,402.18 49.66 8,820.12 74.33
Patients and their families cost – patient’s time and care-giver’s time
Patient loss of working daysa 1,713.08 7.46 889.47 7.50
Informal care 2,250.59 9.80 364.04 3.07
Total (C) 3,963.67 17.26 1,253.51 10.56
Overall (A+B+C) 22,959.08 100.00 11,866.27 100.00
aIf the patient was unemployed, not engaged in housekeeping or retired (≥ 70 
years old), working time was replaced by leisure time. 
Rehab: rehabilitation; Rehab/aboBoNT-A: abobotulinumtoxinA + rehabilitation.
Table III. Base case analysis: cost-utility analysis (2018)
Healthcare programmes Cost, €
Life-years 
saved
Quality-adjusted 
life years
Incremental Cost 
(ΔC), €
Incremental QALYs 
(ΔQALYs)
Incremental cost-utility ratio 
(ΔC/ΔQALYs), €
Italian National Health Service viewpoint
Rehab 1,792.65 1.858 1.150 – – –
Rehab/aboBoNT-A 7,593.23 1.858 1.620 5,800.58 0.470 12,341.23a
Societal viewpoint
Rehab 11,866.27 1.858 1.150 – – –
Rehab/aboBoNT-A 22,959.08 1.858 1.620 11,092.80 0.470 23,600.91b
a95% CI ICUR: €6,206; €42,242. b95% CI ICUR: €8,408; €84,485. 95% CI: 95% confidence interval; ICUR: Incremental Cost; QALYs: quality-adjusted life 
years; Rehab: rehabilitation; Rehab/aboBoNT-A: abobotulinumtoxinA + rehabilitation. 
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and +18.76% (INHS perspective) and –17.25% and 
+25.53% (societal perspective). 
Varying the age the patient enters the CUA model 
has a remarkably skewed effect for societal perspective 
only (from –0.08% to +92.10% vs base case ICUR) 
(Fig. 2B).
Due to the limited time horizon covered by the 
CUA model, the difference in ICURs between the 
first and second years is negligible: +3.19% fol-
lowing the INHS perspective (€12,735 vs €12,341) 
and +3.22% adopting the societal viewpoint (€24,360 
vs €23,601). 
The cost-effectiveness acceptability curve shows 
higher probability for rehab/aboBoNT-A to be cost-
effective as the threshold value for incremental QALY 
gained increases. When the INHS (societal) viewpoint 
is considered, the likelihood that rehab/aboBoNT-A is 
cost-effective is 91.61% (54.32%) for a threshold value 
of €25,000 and 97.30% (84.70%) for a threshold value 
of €40,000 (Fig. 3A and B).
Fig. 2. (A) One-way sensitivity analysis: Italian National Health Service (INHS) viewpoint (2018). Base case incremental cost-utility ratio (ICUR) 
Rehab/aboBoNT-A= €12,341. ICUR: incremental cost-utility ratio; INHS: Italian National Health Service; LL 95% CI: lower limit 95% confidence 
interval; UL 95% CI: upper limit 95% confidence interval; Rehab: rehabilitation; Rehab/aboBoNT-A: abobotulinumtoxinA + rehabilitation. (B) One-
way sensitivity analysis – Societal viewpoint (2018). Base case ICUR Rehab/aboBoNT-A=€23,601; LL 95% CI: lower limit 95% confidence interval; 
UL 95% CI: upper limit 95% confidence interval; Rehab: rehabilitation; Rehab/aboBoNT-A: abobotulinumtoxinA + rehabilitation.
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DISCUSSION 
This is the first Italian economic evaluation aimed 
at comparing costs and QALYs gained with rehab/
aboBoNT-A and rehab via a CUA model, populated 
with data mainly provided by a sample of convenience 
(13) of 3 physiatrists highly experienced in dealing 
with patients with PSS on rehab/aboBoNT-A. 
As far as the Italian setting is concerned, previous 
notable research focused on costs only (29, 30), with 
no attempt to provide cost-effectiveness or cost-utility 
estimates for rehab/aboBoNT-A. 
Regardless of the viewpoint adopted, base case and 
sensitivity analyses show that, compared with rehab, 
rehab/aboBoNT-A is more costly, but gains more 
QALYs. 
It seems noteworthy that post-stroke patients on 
rehab/aboBoNT-A totalled higher costs than those on 
rehab because of the greater number of rehabilitation 
sessions (most of them funded by the INHS in day-
hospital, outpatient or home setting), which, in turn, 
increases the economic burden placed on patients and 
their families (8) due to transportation and parking at 
the healthcare facility, as well as the time devoted by 
the patient and caregiver to healthcare service provision.
From both the INHS and societal viewpoints, the 
base case ICURs for rehab/aboBoNT-A fall below 
the lower limit of the informal acceptability range per 
QALY gained proposed for Italy (€25,000) (23). 
The cost-effectiveness acceptability curve supports 
the high probability for rehab/aboBoNT-A to be cost-
Fig. 3. (A) Cost-effectiveness acceptability curve: Italian National Health Service (INHS) viewpoint (2018). Base case incremental cost-utility ratio 
(ICUR) Rehab/aboBoNT-A=€12,341. Rehab: rehabilitation; Rehab/aboBoNT-A: abobotulinumtoxinA + rehabilitation. (B) Cost-effectiveness acceptability 
curve: society viewpoint (2018). Base case ICUR Rehab/aboBoNT-A=€23,601. Rehab: rehabilitation; Rehab/aboBoNT-A: abobotulinumtoxinA + 
rehabilitation.
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Italian Medicines Agency acknowledged aboBoNT-A 
to be the lowest ex-factory price per U vs other botu-
linum toxins type A reimbursed by the INHS for PSS 
(37). Moreover, our analysis is highly conservative for 
rehab/aboBoNT-A; in practice, it is likely that hospital 
tender discount policies would decrease the purchasing 
price for aboBoNT-A; hence reducing the ICUR for 
rehab/aboBoNT-A accordingly. 
A third limitation concerns utility values used for 
QALYs calculation. As reported for other diseases 
(38), utility values exert a remarkable impact on ICUR 
because of their prominent role in the calculation of 
QALYs. It therefore follows that, all other things being 
equal, different QALYs can lead to diverse decisions 
about the sustainability of rehab/aboBoNT-A when the 
resulting ICURs are contrasted against the threshold 
values adopted in different jurisdictions (38). For rehab 
patients, utility values were collected from a sample of 
US patients with PSS during a 2-year follow-up (16). 
While it is known that patients in different countries 
treated for the same severe disease are likely to return 
similar HRQoL scores (27), notwithstanding it would 
be interesting to compare these values with the utility 
values elicited from a sample of Italian patients with PSS 
on rehab. Following the approach adopted in previous 
research (8, 39), the calculation of QALYs for rehab/
aboBoNT-A patients relies heavily on physiatrists’ opi-
nion. Being aware of the relevance of this assumption 
in influencing the denominator of the ICURs for rehab/
aboBoNT-A, the uncertainty surrounding utility values 
and multiplier was carefully investigated in one-way and 
probabilistic sensitivity analyses. Importantly, replacing 
the baseline estimate of the utility multiplier for calcula-
ting rehab/aboBoNT-A QALYs with the lower limit of 
the 95% CI (i.e. +13.3% vs utility for rehab patients) 
in a one-way sensitivity analysis, the resulting ICURs 
(INHS viewpoint: €38,052; societal viewpoint: €72,769) 
were lower than both the upper limit of the acceptability 
range proposed for Italy (€40,000) (23) and the informal 
threshold value that led the Italian Medicines Agency 
to reimburse cancer drugs (€87,330) (40).
In conclusion, the results of this study show that, 
for both the INHS and society, rehab/aboBoNT-A is 
a cost-effective healthcare programme for treating 
patients with PSS in Italy.
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